🇺🇸 FDA
Pipeline program

MK-3543, MK-3543, MK-3543, MK-3543

MK-3543-017

Phase 3 small_molecule active

Quick answer

MK-3543, MK-3543, MK-3543, MK-3543 for Myeloproliferative Neoplasms (Essential Thrombocythemia, Polycythemia Vera and Myelofibrosis) is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck Sharp and Dohme
Indication
Myeloproliferative Neoplasms (Essential Thrombocythemia, Polycythemia Vera and Myelofibrosis)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials